secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0000950170-23-029662
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics CMO Wayne Godfrey resigns; Chief Strategy Officer Byron Robinson interim lead
--------------------------------------------------------------------------------

- Dr. Wayne Godfrey resigns as CMO effective July 5, 2023 for personal reasons; no disagreement with company.
- Byron Robinson, Ph.D., Chief Strategy Officer, appointed interim head of clinical activities and team.
- Robinson assumes leadership immediately; company emphasizes experienced clinical team remains in place.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/0000950170-23-029662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/janx-20230621.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer